Drug intelligence / Profile preview

radium-224 calcium carbonate microparticles

Lead developer
Oncoinvent Solutions
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intraperitoneal
01

Overview

Radium-224 calcium carbonate microparticles (Radspherin) is an investigational, receptor-independent, alpha-emitting radiopharmaceutical designed for the local treatment of metastatic cancers in body cavities, particularly peritoneal carcinomatosis. Developed by Oncoinvent, the therapy consists of biodegradable calcium carbonate microparticles that act as carriers for the alpha-emitting radionuclide radium-224 (224Ra). Following cytoreductive surgery (with or without hyperthermic intraperitoneal chemotherapy, HIPEC), the microparticles are administered directly into the peritoneal cavity. They distribute throughout the cavity and deliver short-range, high-energy alpha radiation, which induces double-strand DNA breaks in residual microscopic disease and free-floating cancer cells while sparing surrounding healthy tissues. Radspherin is currently being evaluated in Phase 2 clinical trials for peritoneal metastases originating from ovarian and colorectal cancers.

Brand names
Radspherin
Other names
224Ra-CaCO3-MP224Ra-labeled calcium carbonate microparticlesradium Ra 224-labeled calcium carbonate microparticlesradium Ra 224-labeled calcium carbonate microspheresradium-224 calcium carbonate microspheresradium224 calcium carbonate microspheresradium 224 calcium carbonate microspheresradium-224-labeled calcium carbonate microparticlesradium224-labeled calcium carbonate microparticlesradium 224-labeled calcium carbonate microparticles
02

Identity

Drug type
Radiopharmaceuticals
Modality
Antibody-Based TherapeuticsAntibody-Radionuclide Conjugates
03

Pharmacology

Targets

  • DNAirreversible antagonist
Route
Intraperitoneal
04

Development

IndicationHighest phaseStatus
colorectal cancer (CRC) and precursor lesionsIn developmentActive
fallopian-tube cancer and precursor lesionsIn developmentActive
ovarian cancer and premalignant lesionsIn developmentActive
primary peritoneal malignanciesIn developmentActive

Every indication, with countries and timelines, is in the full profile.

05

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

06

Companies

07

Patents & exclusivity

Patents
1

Patent families, expiry dates and exclusivities are in the full profile.

08

Competitive landscape

Drugs on the same target
11
Drugs in the lead indication
1,201

Lead indication: colorectal cancer (CRC) and precursor lesions

Most advanced in the lead indication

  1. afliberceptApproved
  2. bevacizumabApproved
  3. capecitabineApproved
  4. folinic acidApproved
  5. fruquintinibApproved

Beyond the preview

Go deeper on radium-224 calcium carbonate microparticles.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on radium-224 calcium carbonate microparticles.

Work on radium-224 calcium carbonate microparticles? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call